Year: 2024
Resolution Number: 1
Action Taken: Approved
Status: In Progress
Author(s): Lawrence R. Hennessey, MD
Sponsor: Lawrence R. Hennessey, MD
On behalf of: MI Allergy & Asthma Society
Committee: A (Medical Care Delivery)
Resolved Section(s):
RESOLVED: That MSMS affirms the decision to administer subcutaneous versus intravenous immune globulin in the treatment of immune globulin deficiency should be left to the discretion of the patient and their physician and not to the patient’s insurer; and be it furtherRESOLVED: That MSMS opposes insurers limiting access to indicated therapy that would be the safest, most effective, and most convenient option for treatment of immune globulin deficiency; and be it furtherRESOLVED: That MSMS opposes insurers requiring patients to first undergo intravenous immune globulin therapy and only be allowed to receive subcutaneous immune globulin therapy after first suffering debilitating and potentially dangerous side effects; and be it furtherRESOLVED: That MSMS affirms the decision to proceed with subcutaneous versus intravenous immune globulin therapy should be a choice made by the patient and their physician without third party interference.
RESOLVED: That MSMS affirms the decision to administer subcutaneous versus intravenous immune globulin in the treatment of immune globulin deficiency should be left to the discretion of the patient and their physician and not to the patient’s insurer; and be it furtherRESOLVED: That MSMS opposes insurers limiting access to indicated therapy that would be the safest, most effective, and most convenient option for treatment of immune globulin deficiency; and be it furtherRESOLVED: That MSMS opposes insurers requiring patients to first undergo intravenous immune globulin therapy and only be allowed to receive subcutaneous immune globulin therapy after first suffering debilitating and potentially dangerous side effects; and be it furtherRESOLVED: That MSMS affirms the decision to proceed with subcutaneous versus intravenous immune globulin therapy should be a choice made by the patient and their physician without third party interference.
Fiscal Note: $1,000-$2,000
Resolution: View PDF for Guaranteed access to Subcutaneous Immune Globulin Therapy
For More Information, Contact: